 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA has teamed up with a medical college from Cornell University to launch a phase two clinical study investigating Kazias investigational new drug paxalisib in combination with ketogenesis. Specifically, the study will evaluate Kazias paxalisib candidate, in combination with ketogenesis, for treating an aggressive form of cancer known as glioblastoma. 